The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Annual financial impact of well‐differentiated thyroid cancer care in the United States
Open accessAbstract
BACKGROUND: Well‐differentiated thyroid cancer (WDTC) is a prevalent disease, which is increasing in incidence faster than any other cancer. Substantial direct medical care costs are related to the diagnosis and treatment of newly diagnosed patients as well as the ongoing surveillance of patients who have a long life expectancy. Prior analyses of the aggregate health care costs attributable to WDTC in the United States have not been reported. METHODS: A stacked cohort cost analysis was performed on the US population from 1985 to 2013 to estimate the number of WDTC survivors in 2013. Incidence rates, and cancer‐specific and overall survival were based on Surveillance, Epidemiology, and End Results (SEER) data. Current and projected direct medical care costs attributable to the care of patients with WDTC were then estimated. Health care–related costs and event probabilities were based on Medicare reimbursement schedules and the literature. RESULTS: Estimated overall societal cost of WDTC care in 2013 for all US patients diagnosed after 1985 is $1.6 billion. Diagnosis, surgery, and adjuvant therapy for newly diagnosed patients (41%) constitutes the greatest proportion of costs, followed by surveillance of survivors (37%), and nonoperative death costs attributable to thyroid cancer care (22%). Projected 2030 costs (in 2013 US dollars) based on current incidence trends exceed $3.5 billion. CONCLUSIONS: Health care costs of WDTC are substantial. Unlike other cancers, the majority of the cost is incurred in the initial and continuing phases of care. With the projected increasing incidence, population, and survival trends, costs will continue to escalate. Cancer 2014;120:1345–1352. © 2014 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Cited by
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
Cronin, K. A., Lake, A. J., Scott, S., Sherman, R. L., Noone, A., Howlader, N., Henley, S. J., Anderson, R. N., Firth, A. U., Ma, J., et al. (2018) · Cancer · doi:10.1002/cncr.31551 · Cited by 1,485
Nikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404
The changing incidence of thyroid cancer
Kitahara, C. M., & Sosa, J. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.110 · Cited by 1,051
Annual report to the nation on the status of cancer, part I: National cancer statistics
Henley, S. J., Ward, E. M., Scott, S., Ma, J., Anderson, R. N., Firth, A. U., Thomas, C. C., Islami, F., Weir, H. K., Lewis, D. R., et al. (2020) · Cancer · doi:10.1002/cncr.32802 · Cited by 853
Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials
Ito, Y., Miyauchi, A., & Oda, H. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.03.004 · Cited by 295
Metadata
- Authors
- Lubitz, C. C., Kong, C. Y., McMahon, P. M., Daniels, G. H., Chen, Y., Economopoulos, K. P., Gazelle, G. S., & Weinstein, M. C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2014-01-30
- Volume
- 120
- Issue
- 9
- Pages
- 1345-1352
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1916066670
- Cited by
- 188
- References
- 1
- FWCI
- 40.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Annual financial impact of well‐differentiated thyroid cancer care in the United States. https://app.cochat.ai/papers/10.1002/cncr.28562
- The paper
- Lubitz, C. C., Kong, C. Y., McMahon, P. M., Daniels, G. H., Chen, Y., Economopoulos, K. P., Gazelle, G. S., & Weinstein, M. C. (2014). Annual financial impact of well‐differentiated thyroid cancer care in the United States. Cancer. https://doi.org/10.1002/cncr.28562
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.